Mengling Liu

机构：Shanghai Medical College of Fudan University, Fudan University, Fudan University Shanghai Cancer Center, Shenzhen Center for Disease Control and Prevention, Zhongshan Hospital · ORCID：0000-0001-7201-5496

发表论文 35 篇 · 总被引 384 次 · h-index 12

代表论文

• An integrated bioinformatic investigation of mitochondrial solute carrier family 25 (SLC25) in colon cancer followed by preliminary validation of member 5 (SLC25A5) in tumorigenesis (2022 · Cell Death and Disease · 被引 46)
• Solute carriers as potential oncodrivers or suppressors: their key functions in malignant tumor formation (2021 · Drug Discovery Today · 被引 42)
• Application of an extreme learning machine network with particle swarm optimization in syndrome classification of primary liver cancer (2021 · Journal of Chinese Integrative Medicine · 被引 38)
• Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: a narrative review (2022 · Translational Cancer Research · 被引 34)
• Colorectal cancer with BRAF V600E mutation: Trends in immune checkpoint inhibitor treatment (2024 · Critical Reviews in Oncology/Hematology · 被引 21)
• Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy: a multi-center observational study (2024 · Journal of Translational Medicine · 被引 21)